Cargando…
Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
AIMS: To assess the functional and morphological outcome of eyes with neovascular AMD treated with intravitreal ranbizumab following an exit strategy treatment regime. METHODS: The Bern treatment regime for neovascular AMD has a fixed injection schedule, even in the non-active stage of the disease....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145413/ https://www.ncbi.nlm.nih.gov/pubmed/24782472 http://dx.doi.org/10.1136/bjophthalmol-2013-304775 |
_version_ | 1782332171874205696 |
---|---|
author | Menke, Marcel N Zinkernagel, Martin S Ebneter, Andreas Wolf, Sebastian |
author_facet | Menke, Marcel N Zinkernagel, Martin S Ebneter, Andreas Wolf, Sebastian |
author_sort | Menke, Marcel N |
collection | PubMed |
description | AIMS: To assess the functional and morphological outcome of eyes with neovascular AMD treated with intravitreal ranbizumab following an exit strategy treatment regime. METHODS: The Bern treatment regime for neovascular AMD has a fixed injection schedule, even in the non-active stage of the disease. The regimen has been adapted from the PIER study treatment protocol. Eyes with non-active AMD will receive 4 injections in the first year, and 2 injections in the second year of follow-up before treatment stops. Patients that received ranibizumab for treatment and reached the exit criteria were identified, and charts were reviewed to assess functional and morphological outcome. RESULTS: Only 2.6% of all patients (15 out of 575 patients) reached the exit criteria. Mean change in best corrected ETDRS visual acuity (VA) was 4.5±16.9 letters when comparing baseline VA to 4 weeks after the last injection (p=0.32). OCT mean foveal thickness was significantly thinner after last treatment (247.9±43.0 µm) compared to baseline (332.5±83.1 µm, p=0.002). The mean total number of ranibizumab injections was 15.6±8.0, and the mean total treatment period was 40.9±18.3 months. Twenty percent of eyes had geographic atrophy present at baseline versus 46.6% at the end of treatment. CONCLUSIONS: Even with a fixed treatment regime and a defined treatment exit strategy, only a small percentage of patients reach exit criteria. Retinal thickness has been significantly reduced by repeated intravitreal ranibizumab injections, and geographic atrophy became more frequent. |
format | Online Article Text |
id | pubmed-4145413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41454132014-09-02 Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen Menke, Marcel N Zinkernagel, Martin S Ebneter, Andreas Wolf, Sebastian Br J Ophthalmol Clinical Science AIMS: To assess the functional and morphological outcome of eyes with neovascular AMD treated with intravitreal ranbizumab following an exit strategy treatment regime. METHODS: The Bern treatment regime for neovascular AMD has a fixed injection schedule, even in the non-active stage of the disease. The regimen has been adapted from the PIER study treatment protocol. Eyes with non-active AMD will receive 4 injections in the first year, and 2 injections in the second year of follow-up before treatment stops. Patients that received ranibizumab for treatment and reached the exit criteria were identified, and charts were reviewed to assess functional and morphological outcome. RESULTS: Only 2.6% of all patients (15 out of 575 patients) reached the exit criteria. Mean change in best corrected ETDRS visual acuity (VA) was 4.5±16.9 letters when comparing baseline VA to 4 weeks after the last injection (p=0.32). OCT mean foveal thickness was significantly thinner after last treatment (247.9±43.0 µm) compared to baseline (332.5±83.1 µm, p=0.002). The mean total number of ranibizumab injections was 15.6±8.0, and the mean total treatment period was 40.9±18.3 months. Twenty percent of eyes had geographic atrophy present at baseline versus 46.6% at the end of treatment. CONCLUSIONS: Even with a fixed treatment regime and a defined treatment exit strategy, only a small percentage of patients reach exit criteria. Retinal thickness has been significantly reduced by repeated intravitreal ranibizumab injections, and geographic atrophy became more frequent. BMJ Publishing Group 2014-09 2014-04-29 /pmc/articles/PMC4145413/ /pubmed/24782472 http://dx.doi.org/10.1136/bjophthalmol-2013-304775 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Clinical Science Menke, Marcel N Zinkernagel, Martin S Ebneter, Andreas Wolf, Sebastian Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title | Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title_full | Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title_fullStr | Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title_full_unstemmed | Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title_short | Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
title_sort | functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145413/ https://www.ncbi.nlm.nih.gov/pubmed/24782472 http://dx.doi.org/10.1136/bjophthalmol-2013-304775 |
work_keys_str_mv | AT menkemarceln functionalandanatomicaloutcomeofeyeswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumabfollowinganexitstrategyregimen AT zinkernagelmartins functionalandanatomicaloutcomeofeyeswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumabfollowinganexitstrategyregimen AT ebneterandreas functionalandanatomicaloutcomeofeyeswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumabfollowinganexitstrategyregimen AT wolfsebastian functionalandanatomicaloutcomeofeyeswithneovascularagerelatedmaculardegenerationtreatedwithintravitrealranibizumabfollowinganexitstrategyregimen |